Moreover, combination of hIL15-ABD with a rat antibody against murine PD-L1 antibody, 10F.9G2, demonstrated greater anti-tumor effect than that of either monotherapy, by enhancing the activity of anti-tumor effector cells associated with both innate and adaptive immunities as well as decreasing the TME’s immunosuppressive cells. This evidence concerns the gene CD274 and neoplasm.